Sign In
Buy DTIL
$6.04
-0.280 (-4.43%)
At Close: Jun 03, 2026
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
07:01am, Wednesday, 19'th Nov 2025
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
Precision BioSciences, Inc. ( DTIL ) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B November 11, 2025 8:00 AM EST Company Participants Naresh Tanna - C
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
06:12pm, Monday, 10'th Nov 2025
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo g
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update
07:01am, Monday, 03'rd Nov 2025
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025
07:01am, Friday, 31'st Oct 2025
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last?
09:06am, Thursday, 16'th Oct 2025
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025
07:01am, Tuesday, 14'th Oct 2025
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial
07:01am, Tuesday, 07'th Oct 2025
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
Precision BioSciences, Inc. (DTIL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
05:52am, Tuesday, 16'th Sep 2025
Precision BioSciences, Inc. (NASDAQ:DTIL ) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 10:00 AM EDT Company Participants Michael Amoroso - President, CEO & Director Cass
Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status
07:01am, Monday, 08'th Sep 2025
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
DTIL Revenue Drops 99%
11:13am, Thursday, 07'th Aug 2025
Precision BioSciences (DTIL -3.12%), a clinical-stage biotechnology firm focused on gene editing, released its Q2 FY2025 earnings results on August 7, 2025. The main headline: GAAP revenue dropped to
Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates
10:26am, Thursday, 07'th Aug 2025
Precision BioSciences (DTIL) came out with a quarterly loss of $2.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $3.46 per share a year ago.
